All posts by imreal

etherFAX Announces Partnership with Vivlio Health to Improve Interoperability


News Image

etherFAX today announced its partnership with Vivlio Health, a leading provider of workflow automation technology for healthcare organizations. As part of the partnership, Vivlio Health will utilize the etherFAX Secure Exchange Network (SEN) to receive incoming faxes, clinical data, and high-resolution, color documents with ultra-fast transmission speeds and end-to-end encryption.

etherFAX SEN, a patented Infrastructure-as-a-Service solution, leverages a hybrid-cloud technology to provide 100% secure communications and data protection. With over six million connected endpoints, etherFAX SEN is the world’s largest fax network supporting every major fax server, application, and fax-enabled device. Most recently, the etherFAX service achieved HITRUST Risk-based, 2-year Certification to further mitigate risk in third-party privacy, security, and compliance.

“We look forward to providing Vivlio Health with fast and secure fax communications,” said Paul Banco, CEO and co-founder of etherFAX. “The intelligence and reliability of our network is unparalleled. Together with Vivlio Health, we are enabling healthcare information to be easily shared, accessed, and analyzed.”

As a result of this partnership, physicians utilizing Vivlio’s interoperability platform can serve patients faster, with fewer errors, as the result of receiving pertinent medical record history via etherFAX.

“We are proud to partner with etherFAX as we continue to deliver innovative technology to the healthcare community,” said Matthew Halkos, CEO at Vivlio Health. “etherFAX’s secure document delivery solutions allow us to maintain the highest level of security for sensitive patient data and complete a vital component of our interoperability offering.”

As a cloud-based solution, etherFAX does not require a fax server or additional software. etherFAX and Vivlio Health can be easily integrated into existing workflows and customized to meet specific customer requirements.

About Vivlio Health

Founded in 2020, Vivlio Health offers a secure, cloud-based application to the clinical care team that simplifies and streamlines the process to acquire and transfer medical records and images. At its core, Vivlio serves healthcare providers who serve patients. Accessing vital clinical data and making it quickly and easily available improves patient care, decreases the labor-intensive tasks involved in assembling this data, and increases the number of patients a health system can serve. For more information, visit us at http://www.vivliohealth.com, or call us at 404-777-5772.

About etherFAX

Founded in 2009, etherFAX® offers a secure document delivery platform and suite of applications widely used across a broad range of industries to digitize workflows and optimize business processes. As a leading provider of hybrid-cloud fax solutions supporting healthcare enterprises, etherFAX securely transmits protected health information and high-resolution, color documents directly to applications and devices with end-to-end encryption and ultra-fast transmission speeds. etherFAX’s secure, cloud-based, and encrypted data exchange solutions operate in a HIPAA and SOC 2® compliant environment that is both HITRUST CSF® and PCI DSS certified. For more information, visit http://www.etherfax.net, follow us out on LinkedIn at https://www.linkedin.com/company/etherfax, call us at 877-384-9866, or email sales@etherfax.net.

# # #

Share article on social media or email:

Patient-Centric Approaches, Upcoming Webinar Hosted by Xtalks


Trials and studies in rare and pediatric diseases typically have little or no previous track record in clinical research, so feedback from children, parents and patients is especially important

The phrase “patient-centricity” can mean many things but at heart it means designing a treatment, clinical trial, or other healthcare solution based on what the patient or their family needs or wants. For clinical researchers, it means making the clinical trial process the easiest and best it can be, from the patient or family’s perspective. A patient-centric approach should start at the time a study or trial is devised. Clinical trial design is one of the most important places to involve the patient voice. For pediatric rare disease natural history studies or therapeutic trials, it is especially important.

This is because trials and studies in rare and pediatric diseases typically have little or no previous track record in clinical research, so feedback from children, parents and patients is especially important, as they know more about the disease than anyone else.

Possible options include hosting patient groups, working with patient advocacy organizations, or analysing real-world evidence (assuming there is some), so that trial eligibility criteria reflect the patient population.

It is also important to realize that a pediatric research patient really needs family. Thought must be given toward the accommodation of the patient, parent(s) and siblings, even for a study of short duration. It is recommended to incorporate patient/family reimbursement into the study contract as well as ensuring participating site(s) have processes/infrastructure to minimize family burden by supporting a “family” during clinic visits.

Register to learn about undertaking patient-centric approaches in pediatric rare disease studies and clinical trials.

Join experts from TFS HealthScience, Scott Schliebner, Senior Vice President, Clinical Development Services Head of Rare Diseases and Orphan Drugs; and Alison Sampson, PhD, Head of Rare Diseases and Orphan Drugs, Europe, for the live webinar on Wednesday, September 14, 2022, at 11am EDT (4pm BST).

For more information, or to register for this event, visit Pediatric Rare Disease Studies: Patient-Centric Approaches.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

ThriveAP Appoints James B. Creason as President & Chief Executive Officer


“We are thrilled to welcome Jim to ThriveAP. His high energy and growth-oriented approach will build upon our mission to support advanced practice providers nationwide in the delivery of comprehensive transition to practice solutions,” said Will Fitzgibbon on behalf of ThriveAP’s Board of Directors.

ThriveAP announced today the appointment of James (Jim) B. Creason as President and Chief Executive Officer. He will also serve on the Company’s Board of Directors.

An exceptional entrepreneur and business leader, Creason will bring more than 35 years of experience to the company, including a wide range of involvement in and around the healthcare ecosystem. Creason will drive the strategic vision of ThriveAP as the nation’s most trusted resource in transition to practice education.

Commenting on his appointment, Creason said, “The opportunity to become involved with the ThriveAP team was an opportunity I could not pass up. Management intends to continue to leverage the current program offerings to grow our existing employer enterprise clients while also increasing the velocity of new program offerings from our program development roadmap.”

“We are thrilled to welcome Jim to ThriveAP. His high energy and growth-oriented approach will complement the ThriveAP team’s entrepreneurial style and will build upon our mission to support advanced practice providers nationwide in the delivery of comprehensive transition to practice solutions,” said Will Fitzgibbon on behalf of ThriveAP’s Board of Directors.

Prior to joining ThriveAP, Creason served much of his 16+ year tenure as the Chief Operating Officer of Censis Technologies, Inc. (Censis), a healthcare technology company, Censis was acquired by Fortive Corporation.

About ThriveAP

Founded in 2012, ThriveAP is a transition to practice solution for Advanced Practice Providers and their employers throughout the nation. ThriveAP’s educational program helps facilitate the growing impact of APPs in the delivery of healthcare and is recognized for its quality, relevance, and convenience. The ThriveAP program blends interactive educational experiences, community, and support to improve provider productivity, proficiency, and confidence through real-world skill development. Learn more, ThriveAP.com

Share article on social media or email:

Polpharma Chooses CARA Life Sciences Platform for PV Case Management and E2B R3 Compliance


The Generis team impressed us with their efficient project planning and willingness to work towards our requirements; Generis are truly working with us to make sure the CARA platform meets all of our needs.

Polpharma, founded in 1935, is the leader of the Polish pharmaceutical market and one of the leading drug manufacturers in the region of Central and Eastern Europe. They offer modern drugs, substances, and innovative solutions for patients and business partners from around the world.

Like many other companies at the moment, Polpharma was looking for a platform which would ensure E2B R3 compliance and provide capabilities for PV case management. With the CARA Life Sciences Platform, PV cases can be created in CARA from different input sources (XML input, emails, manual entry), and then processed to closure, providing full traceability and reporting.

“We were looking for a system which would give us control and compliance,” said Krzysztof Karpiński, QPPV, Chief of PV & MI, Polpharma, “but it was the flexibility and configurability of CARA which we appreciated the most. The Generis team impressed us with their efficient project planning and willingness to work towards our requirements; Generis are truly working with us to make sure the CARA platform meets all of our needs.”

The CARA Life Sciences Platform offers companies the opportunity to unify their entire R&D landscape with the unique ‘information lake’ concept for managing data, documents, and other forms of content. This allows users to input the information once and easily re-use it, which reduces duplication of work and allows for greater efficiency across the organisation.

“We are excited to be able to welcome a forward-thinking company like Polpharma to our customer family,” commented James Kelleher, CEO of Generis, “as well as to expand our client base in the area of Safety and PV Case Management, especially with companies who are looking to consolidate their numerous separate systems onto a single platform. For professionals working within Safety, one of the key benefits is the ability to effectively connect Safety data with their Clinical and Regulatory information, something made easy with the CARA Life Sciences Platform.”

About Polpharma

Polpharma is a part of a strong international pharmaceutical group, offering modern drugs, substances and innovative solutions for patients and business partners from around the world. 400 million packages leave out company’s manufacturing plants every year. The mission of Polpharma is to help people live a healthy life in a healthy world. Thanks to a wide portfolio of products from many therapeutic groups, the company can support patients in the treatment and prevention of the most common diseases. More at polpharma.pl

About Generis

Generis is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis’ flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at generiscorp.com

Share article on social media or email:

Betterbrand Releases First-of-Its-Kind Respiratory Gummy Supplement Featuring IMMUSE™


BetterLungs® Immunity with IMMUSE™

Supporting immune system health is more important than ever, and we are pleased to see our IMMUSE™ ingredient formulated into a Betterbrand product, knowing the care and attention paid to bringing this innovative formulation to market

Betterbrand recently added a new product to their respiratory and immune health supplements lineup: BetterLungs® Immunity with IMMUSE™ that rolled out in 1,000+ CVS stores nationwide. This first-ever respiratory gummy to feature IMMUSE™ was designed to support respiratory health; help reduce fatigue from exercise; provide clinically researched, year-round immune support; and help with work productivity by supporting the immune system.*

Developed by Dr. Chris Jackson, Pharm.D, Betterbrand was the culmination of years of research and planning to help everyone live a better and more balanced life through natural, effective products. “Watching my grandma struggle with respiratory issues drove me to want to help the millions of others suffering with the same health issues,” said Dr. Chris. “However, in pharmacy school I realized there was an enormous opportunity to change lives through education and empowerment beyond respiratory support.”

Before incorporating it into their product, Betterbrand put IMMUSE™ through a rigorous process of consideration that is standard at the company. They thoroughly researched IMMUSE™, cross-referencing its claims with current scientific research to vouch for its safety, function, and potential interactions. They also ensured quality at the production source, iterated different ingredient ratios before settling on an optimal formulation, and tested their final product with a third-party lab.

“Supporting immune system health is more important than ever, and we are pleased to see our IMMUSE™ ingredient formulated into a Betterbrand product, knowing the care and attention paid to bringing this innovative formulation to market,” commented Karen Todd, MBA, RD, Vice President Global Brand Marketing, Kyowa Hakko USA, Inc.

Each daily BetterLungs® Immunity with IMMUSE™ gummy contains 50 mg of IMMUSE™ LC-plasma, a postbiotic that proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells)*. The pDC, a rare type of immune cell, has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*.

IMMUSE™ is backed by 29 published studies, including 14 human clinical trials, and over 10 years of research. It won the 2021 Frost & Sullivan North American Immune Health Ingredient and New Product Innovation Award, and it is distributed by Kyowa Hakko, an international ingredients manufacturer whose primary goal is to provide health solutions that support optimal health for improved quality of life.

BetterLungs® Immunity with IMMUSE™ can be purchased on the Betterbrand website at https://www.trybetterbrand.com/products/better-lungs-immunity. To learn more about IMMUSE™, go to https://immusehealth.com/.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About IMMUSE:

IMMUSE™ is a postbiotic that delivers a new, breakthrough approach to broad range immune support*. As a clinically researched immune activator* supported by 29 published studies, including 14 human trials, IMMUSE™ proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells)*. The pDC, a rare type of immune cell, functions as the a key leader of the immune system and has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*. Its unique mechanism of action, discovered by Kyowa Hakko’s parent company Kirin Holdings Co., Ltd., is opening doors for discovering postbiotics concerning immune health.

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™ Lacticaseibacillus paracasei KW3110, Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com..

About Dr. Chris Jackson, Pharm:

Dr. Chris Jackson is the founder and CEO of Betterbrand. Dr. Jackson trained at the University of Texas at Austin and had published several research projects to advance the use of rapid diagnostics in the field of infectious diseases. He served as a Combat Medic and Infantry Officer in the US Army.

About Betterbrand

Founded in 2019, Betterbrand aims for “better living through science” and designs data-backed products made from natural ingredients. Each product developed is reviewed by medical doctors in their internal Medical Advisory Committee and tested by Eurofins Scientific. Betterbrand offers premium products at affordable prices.

Media interested in setting up an interview with Karen Todd, please contact Giselle Chollett: giselle@adinnyc.com or 917.386.7116.

Share article on social media or email:

CABRI Announces Call for Proposals on Specialized Pro-Resolving Mediator Analytical Methods


There is a critical need for basic research on analytical methods used for specialized pro-resolving mediators (SPMs). CABRI is offering research grants in amounts up to $100,000 to support this need.

The Cayman Biomedical Research Institute (CABRI) is pleased to announce a call for proposals that support essential research on specialized pro-resolving mediator (SPM) analytical methods.

There is a critical need for basic research on analytical methods used for specialized pro-resolving mediators (SPMs). SPMs are a family of lipid metabolites derived from polyunsaturated fatty acids (PUFAs) that promote the resolution of inflammation and have been detected in several experimental models and human conditions. However, researchers using mass spectrometry-based methods have been in conflict with each other, and do not agree on how much, if any, SPMs are present in biologically relevant contexts. Hence, continued research on SPM analytical methods is necessary for this field to move forward.

CABRI is offering research grants in amounts up to $100,000 to support this need. We encourage anyone seeking to provide clarity to SPM analytical methods to apply for these research grants.

Research proposal applications may be submitted on the CABRI website at http://www.cabrimed.org. These applications will be reviewed on a rolling basis.

CABRI is a nonprofit foundation that supports research on rare illnesses and orphan diseases. As part of CABRI’s commitment to the greater scientific community, CABRI awards research grants to academic scientists that address basic science research objectives with the highest unmet needs.

Share article on social media or email:

CABRI Announces Undergraduate Fellowships and Scholarship Program


Hands-on research is an equally valuable learning experience that introduces a student to a potential career path and fosters the growth of their talents.

The Cayman Biomedical Research Institute (CABRI) is pleased to announce that applications for our undergraduate fellowships and scholarship program are open.

Undergraduate fellowships are available on a competitive basis to undergraduate students who have been offered an unpaid research position by a qualified principal investigator. Up to $5,000 per semester is available to each mentee-mentor team, with the entire amount paid as compensation to the undergraduate. The principal investigator will be responsible for the mentorship and guidance of the student during the period of the award.

“These fellowships are an excellent training opportunity for undergraduates to expand their knowledge outside the lecture hall,” said Kourtney Goode, Academic Relations Coordinator at Cayman Chemical. “Hands-on research is an equally valuable learning experience that introduces a student to a potential career path and fosters the growth of their talents.”

Undergraduate fellowship applications may be submitted on the CABRI website from August 22nd to September 18th, 2022, and awardees will be notified by October 16th, 2022.

As part of CABRI’s commitment to help college-bound students continue their education after losing a parent or guardian to sinonasal undifferentiated carcinoma (SNUC) or B-cell lymphoma, scholarships are available to support the continued education of these students.

Scholarship applications are accepted throughout the year and are available on the CABRI website at https://www.cabrimed.org/scholarships/.

CABRI is a nonprofit foundation that helps reduce the impact of rare diseases by funding research and supporting expanded opportunities for emerging scientists and families affected by these diseases.

Share article on social media or email:

Winners of Blueprint Prep’s $20,000 Law School Tuition Scholarship Announced


Blueprint Prep, a premier education company specializing in support for lifelong professional advancement and test preparation, is pleased to announce the winners of its 2021 and 2022 law school tuition giveaway. Arianna Wright, the 2021 winner, studies at Washington & Lee University School of Law in Virginia, and Maribel Zetina, the 2022 winner, is completing her undergraduate degree at Southern New Hampshire University and plans to enter law school in 2023.

The scholarship awards one student per year $20,000 that can be used towards law school tuition. Now in its 2nd year, the scholarship is just one of many ways Blueprint Prep is achieving its goal of helping underrepresented students overcome the barriers they face in pursuing legal careers. Having helped over 100,000 LSAT students so far improve their admissions prospects with higher test scores, the company views the tuition scholarship as an important complementary strategy to open opportunities for more students.

“Whether they are just beginning their legal journey or they are 30 years into it, law students and practicing lawyers need the best resources they can get to meet the challenges of a competitive, demanding profession,” says Matt Riley, CEO and Founder of Blueprint Prep. “We’re grateful that we’re able to offer some assistance to these two exemplary students, and we’re excited to see what they go on to achieve.”

Arianna Wright has a background in politics, with an undergraduate degree in political science and an internship on Capitol Hill in Washington, D.C. with a congressional member of Georgia’s 13th district. Her interest in public policy and law in general, along with a close family member’s influence, inspired her to apply to law school.

“I’ve been interested in the law since I was young. I remember hearing stories about my uncle’s work—he was an assistant US attorney at one point—and I found them fascinating,” says Wright. “I can’t believe that all these years later I’ve been given this amazing opportunity. I intend to take full advantage of the Blueprint Prep scholarship to get my legal career off to a great start.”

Maribel Zetina is a mother of two currently completing her Criminology major. While working in the insurance industry, she noticed a pattern of claims being mishandled in ways preventable by sound legal representation. Disturbed by this, she realized that preventing these sorts of injustices and advocating for people in their times of greatest need was how she wanted to spend her life.

Shortly after, she applied to law school, and she describes the process as “exhilarating, draining, and everything in between.” But winning the Blueprint Prep scholarship has confirmed to her beyond a doubt that she made the right choice to pursue her dream of a legal career. “It meant everything to me to win,” Zetina says. “It completely lit up the path, and there’s nothing that’s going to stop me now.”

With many other talented students waiting in the wings for a chance to fulfill their potential, Blueprint Prep is refining its existing solutions and looking for new ways to give aspiring lawyers the support they need. Blueprint Prep plans to open the application process for next year’s law school tuition scholarship sometime in the first quarter of 2023.

To learn more about Blueprint Prep’s lifelong professional prep solutions for law students and practicing lawyers, visit https://blueprintprep.com/lsat.

About Blueprint Prep

Founded in 2005, Blueprint Prep is the leading platform for high-stakes test prep in the U.S., offering live and self-paced online courses, private tutoring, self-study materials, and application consulting services for pre-law, pre-med, and medical school students, as well as Qbanks, tutoring, and live study groups for residents, practicing physicians, PAs and NPs via its recent acquisitions of Rosh Review and Sarah Michelle NP Reviews. Blueprint Prep leverages a unique approach that combines engaging video lectures, unparalleled expertise in content creation, the latest adaptive learning technology, and personalized study planning tools. Blueprint Prep has produced unrivaled results, including industry-leading score increases for its pre-law and pre-med students taking the LSAT and MCAT.

Share article on social media or email:

Axes Physical Therapy Celebrates Opening of 16th and 17th Locations in Ballwin and St. Peters, MO


Physical Therapy Ballwin MO

Axes Physical Therapy

Our people are our product. Each person on the team, past and present, has contributed to our upward trajectory and created a genuine, lively, warm environment for anyone who walks through the door at Axes. They are centered on positively impacting and improving the lives of the people we serve.

Axes Physical Therapy is a full-service physical and occupational therapy provider now with 17 locations. Axes proudly serve the Greater St. Louis, MO area with clinics located in St. Louis County, St. Charles County, Jefferson and Franklin Counties, and St. Francois County.

The name Axes (ak-sēz) is defined as a place of great importance to an activity or interest. For Axes Physical Therapy, that interest is returning our patients to the activities they love through hands-on, expertly provided physical and occupational therapy services.

Since opening in May 2016 with two locations and the desire to change the physical therapy landscape in the Midwest, Axes has quickly become a place of great importance to patients and the caring employees who make up the team with 17 locations, and growth on the horizon. Staying true to their roots, Axes is a local company, owned and operated by physical therapists.

In 2021 and 2022, Axes was nominated for Best Physical Therapy in St. Louis by STL Magazine and Best Places to Work in St. Louis by the St. Louis Post Dispatch. These nominations are a true testament to the quality of their services and the strength of the company culture. Also in 2022, Axes received the Community Impact Award from the St. Louis Business Journal for their goodwill donations of money and time through the Axes Physical Therapy Foundation.

In August 2022, Axes opened its newest facilities, offering quality physical therapy in Ballwin and St. Peters, MO. The first physical therapy clinic is in St Peters, making this their second location servicing the St. Peters community. This new location, led by John Ruesler, PT, DPT, CMPT near 70/370, in between Mid Rivers Mall Drive and Cave Springs exits. The second location is in Ballwin, just off Manchester Rd/ 141, led by Emily Helton, Clinic Director, PT, DPT, CMPT, Astym Cert.

Over the past 6 years, Axes has received astounding amounts of support from community members, the medical community, patients, friends, family, and clients. This support allowed them to grow from two to 17 locations, with over 150 employees, despite the challenges presented in 2020.

Axes Partner and Director of Business Development, Bruce Watson, attributes their success to the caliber, knowledge, and spirit of their employees. “Our people are our product. Each person on the team, past and present, has contributed to our upward trajectory and created a genuine, lively, warm environment for anyone who walks through the door at Axes. They are centered on positively impacting and improving the lives of the people we serve.”

Share article on social media or email:

LA County DHS Implements Upgrade with Apollo Enterprise Imaging to Address Suspected Abuse Image Management


The Apollo arcc clinical image management system provides the functionality we need to support our patients, while at the same time providing the security around these sensitive images all the way through the care journey,

Apollo, the leading provider of enterprise imaging and clinical multimedia management solutions, today announced that Los Angeles County Department of Health Services implemented the Apollo Enterprise Imaging Solution, arcc® as an upgrade from Apollo EPMM®. arcc (The Apollo Repository for Clinical Content), provides the complexity and security needed to support the LA County DHS Medical Hub Clinics to address Suspected Child Abuse and Neglect (SCAN) image management. The LA County Medical Hub Clinics provide high quality, coordinated health care for children who are involved with the Department of Children and Family Services (DCFS).

“The Apollo arcc clinical image management system provides the functionality we need to support our patients, while at the same time providing the security around these sensitive images all the way through the care journey,” said Dr. Janet Arnold-Clark, Senior Physician, Martin Luther King, Jr. Pediatric Hub.

Suspected Abuse and Neglect is a unique clinical area that has significant security restrictions and workflows that do not conform to workflows seen in other clinical areas of the health system. Professionals involved in these cases extend beyond the walls of the hospital to include first responders, law enforcement, social workers, and the justice system.

SCAN situations require a delicate approach and the consultation of SCAN professionals to assist first responders in the determination of abuse cases. These special cases require a diverse team to work together for the protection and care of children. Having a secure tool to capture and record potential abuse cases has provided a critical component missing in the SCAN care process. The arccMobilehttps://www.apolloei.com/arccmobile.html application provides a secure solution and user experience to assist in the capture and exchange of information with clinicians.

About Apollo

Apollo is a healthcare IT company with a reputation for delivering quality Enterprise Imaging solutions that address both clinical multimedia workflow management needs and vendor neutral storage requirements. Apollo’s Enterprise Imaging solution, arcc, provides a holistic longitudinal view of all patient data and focuses on clinical workflows, interoperability, and connectivity so that every department throughout the entire enterprise can securely acquire, view, manage, store, and access all clinical content for “one patient view” through one platform. Used successfully in hospitals across the United States and Canada for 28 years, visit https://www.apolloei.com/ to learn more.

Share article on social media or email: